All In Biotech

Drug Trial Radar · NCT03933280

Conscious Sedation for Cataract Operations Under Topical Anaesthesia

Nalbuphine/Dexmedetomidine Versus Nalbuphine/Propofol Conscious Sedation for Cataract Extraction Under Topical Anaesthesia: A Double-Blind Randomized Trial

Last checked: Nov 20, 2026Latest source record: Jan 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Jul 1, 2019

Primary completion

Dec 1, 2020

Study completion Jan 1, 2021

Sponsor

Lead sponsor
Menoufia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Topical anaesthesia of the eye for ophthalmologic procedures avoids pain and discomfort of local anaesthetic injection in the peribulbar or retrobulbar block so that patient comfortability is achieved. Sedation during topical anaesthesia of the eye is mostly required to achieve anxiolysis, amnesia and keeping the patient calm all through the procedure. In the present study, the investigators will investigate the effect of nalbuphine/dexmedetomidine versus nalbuphine/propofol on the sedation as a primary outcome, intra-operative, postoperative analgesia, vital signs, patient and surgeon satisfaction and side effects as secondary outcomes

Conditions

  • Conscious Sedation

Interventions

  • NalbuphineDrug

    i.v. nalbuphine bolus of 50 μg/kg.

  • PropofolDrug

    A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min

  • DexmedetomidineDrug

    i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.

  • Benoxinate Hydrochloride 0.4% Eye DropsDrug

    Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sedation scoreTime frame: perioperative

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Faculty of Medicine

    Cairo, Shebin El-kom, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.